Commissioning Cancer Medicines 2013

Wednesday 20th November 2013
Pullman London St Pancras Hotel


Professor Adrian Newland

Clinical Member London North East,
Chemotherapy CRG


Professor Peter Clark

Chair, Chemotherapy CRG

Commissioning Cancer Medicines 2013

Wednesday 20th November 2013
Pullman London St Pancras Hotel

This conference was aimed at NHS England organisations, which included representatives from Local Area Teams, Cancer and Chemotherapy CRGs, Strategic Clinical Networks, Clinical and Management Directors from Provider Trusts, UK technology appraisal groups, Clinical Commissioning Groups (CCGs) and other healthcare professionals with an interest in the planning and commissioning of cancer services.

Key topics included:

  • NHS England and cancer care
  • The Cancer Drugs Fund in 2013
  • Value-based pricing and issues of affordability
  • Stratified medicine for cancer
  • Challenges of introducing new medicines for cancer
  • SACT dataset

What others said about last year's event

"Thank you for asking me, I thought it was an excellent event, I really enjoyed the programme, good venue and very smooth and slick organisation."

"LCNDG conference is the highlight of my conference year"

"Very enjoyable with an excellent range of speakers sharing their expertise and, knowledge and skills"

"All the speakers were very valuable and it was a thought inspiring day"

"I liked the focus this year less on drugs and more on aspects such as Cancer Drug Fund, stratified medicine and development for the future. Great day"

"Excellent, gets better year in year. Really useful, positive day. Thank you"

View photos from the 2013 conference


09.30 - 10.00 Arrival, registration, refreshments and exhibition

Morning session:
Chair: Adrian Newland, Clinical Member London North East, Chemotherapy CRG

Time Session
10.00 – 10.10

Welcome and introduction
Adrian Newland, Clinical Member London North East,
Chemotherapy CRG

10.10 – 10.35 NHS England and cancer care
Sean Duffy, National Clinical Director for Cancer, NHS England
10.35 – 11.00 Stratified medicine and the future for cancer care
Ultan McDermott, Career Development Fellow and Group Leader, Cancer Genome Project, Wellcome Trust Sanger Institute
11.00 – 11.20 Questions from the audience
Facilitated by Adrian Newland
11.20 – 11.45 Refreshments and exhibition
11.45 – 12.10 Emerging picture of value-based pricing
Helen Knight, Associate Director, Technology Appraisals, National Institute for Health and Care Excellence
12.10 – 12.35 Addressing the affordability of cancer medicines
Eric Low, Chief Executive, Myeloma UK
12.35 – 13.00 Questions from the audience
Facilitated by Adrian Newland
13.00 – 14.00 Buffet lunch and exhibition

Afternoon session:
Chair: Peter Clark, Chair, Chemotherapy CRG

Time Session
14.00 – 14.05 Overview of the afternoon session
Peter Clark, Chair, Chemotherapy Clinical Reference Group
14.05 – 14.30 Systemic anti-cancer therapy (SACT) dataset-what have we learnt?
Ken Lloyd, Clinical Information Consultant to the National Cancer Intelligence Network (NCIN) and Kellie Peters, Programme Lead for the Chemotherapy Intelligence Unit
14.30 – 14.45 Questions from the audience
Facilitated by Peter Clark
14.45 – 15.10 Refreshments and exhibition
15.10 – 15.35 Introducing new medicines for rare cancers—challenges for industry and NHS England
Rob Drury-Dryden, Former Director of Oncology Merck Serono
15.35 – 16.00 The national cancer drugs fund—where are we now?
Peter Clark, Chair, Chemotherapy CRG
16.00 – 16.25 Questions from the audience
Facilitated by Peter Clark
16.25 – 16.30 Conference close


Pullman London St Pancras Hotel is a central London hotel, close to the King's Cross and St. Pancras stations. A four star hotel, it has 312 non-smoking rooms with contemporary style as well as LCD TVs and Internet access.

There is a fully-equipped fitness center. 16 state of the art meeting rooms welcome up to 446 guests, perfect for presentations or wedding parties. All have wireless Internet.

Click here for detailed directions to Pullman London St Pancras Hotel


We thank the sponsors of the 2013 London Cancer New Drugs Group meeting for their support.

This meeting has been supported by the pharmaceutical industry by purchasing exhibition stand space

If you are interested in sponsoring the 2013 meeting, please contact Anthony O'Rawe on: 01494 549 103 or email:


Adrian Newland

Adrian Newland Full biog

Adrian Newland is Professor of Haematology at Barts and The London School of Medicine and Dentistry, where he was Clinical Director of the North East London Cancer Network until 2013 and is now Clinical Advisor to the North and East London Cancer Commissioning Support Unit.

Peter Clark


Peter Clark Full biog

Professor Peter Clark has been a Medical Oncologist in Liverpool for over 20 years, particularly working in cancer units and linking with the cancer centre.

Sean Duffy

Sean Duffy Full biog

Sean Duffy is National Clinical Director for Cancer and a clinical academic gynaecologist based at the University of Leeds, with his clinical practice at the city’s St James’s Hospital.

Ultan McDermott

Ultan McDermott Full biog

Ultan McDermott is a clinician scientist with an interest in cancer genomes and how they impact on drug response in the clinic. He is a group leader in the Wellcome Trust Sanger Institute as well as a practicing oncologist at Addenbrooke’s Hospital, Cambridge.

Helen Knight

Helen Knight Full biog

Helen Knight is Associate Director of the Technology Appraisals team at NICE. She graduated from the University of Leeds with a degree in biochemistry and has also obtained a postgraduate certificate in health economics from the University of Aberdeen.

Eric Low

Eric Low Full biog

Eric Low is Chief Executive of Myeloma UK and has been involved in the field of myeloma for around 20 years. Under Eric’s direction Myeloma UK has grown and developed and is the only organisation in the UK dealing exclusively with myeloma.

Ken Lloyd

Ken Lloyd Full biog

Ken Lloyd is Clinical Information Consultant to the NCIN. He was previously a Consultant Clinical Oncologist and Trust Chief Executive at Northampton General Hospital. For many years, he was an Information Consultant to the Clinical Information Analysis (CIA) programme, and was instrumental in its development.

Kellie Peters

Kellie Peters Full biog

Kellie Peters has recently taken the programme lead role for implementing the Systemic Anti-Cancer Therapy (SACT) systems and processes, alongside developing a data audit system for the Cancer Drugs Fund.

Rob Drury-Dryden

Rob Drury-Dryden Full biog

Rob Drury-Dryden is Former Director of Oncology, Merck Serono. He studied biochemistry at the University College of Wales, Aberystwyth, before pursuing research into brain peptides in horses as his Masters degree. Rob joined the pharmaceutical industry in 1997, project managing for a dermatological development company, and then spent 6 years running the international sales & marketing team for Theramex, the women’s health arm of the Merck Group.